JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

University of Cologne12 enrolled

Overview

The Purpose of this trial is: * to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL * to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Recurrent Classical Hodgkin Lymphoma

Interventions

RuxolitinibDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * relapsed or refractory HL * ECOG \<= 2, * no major organ dysfunction * written informed consent Exclusion Criteria: * history of another primary malignancy ≤ 2 years * female patients who are pregnant or breast feeding * patients with a known history of HIV seropositivity * chronic active hepatitis

Locations (1)

1st Dept. of Medicine, Cologne University Hospital

Cologne, Germany

Outcomes

Primary Outcomes

overall response rate

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.